BerGenBio ASA (OSL:BGBIO) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BerGenBio ASA's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BerGenBio ASA could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BerGenBio ASA's Cash-to-Debt or its related term are showing as below:

OSL:BGBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 65.59 Med: 3135.83 Max: No Debt
Current: 280.74

During the past 9 years, BerGenBio ASA's highest Cash to Debt Ratio was No Debt. The lowest was 65.59. And the median was 3135.83.

OSL:BGBIO's Cash-to-Debt is ranked better than
84.24% of 1523 companies
in the Biotechnology industry
Industry Median: 6.39 vs OSL:BGBIO: 280.74

BerGenBio ASA Cash-to-Debt Historical Data

The historical data trend for BerGenBio ASA's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BerGenBio ASA Cash-to-Debt Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

432.01

357.28

268.57

548.38

373.13

BerGenBio ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															112.30	No Debt	1,676.38	373.13	No Debt

Competitive Comparison of BerGenBio ASA's Cash-to-Debt

For the Biotechnology subindustry, BerGenBio ASA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BerGenBio ASA's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's Cash-to-Debt falls into.

BerGenBio ASA Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BerGenBio ASA's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	155.969	/	(0.418	+	0)
	=	373.13

BerGenBio ASA's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

BerGenBio ASA had no debt ⁽¹⁾.

BerGenBio ASA (OSL:BGBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BerGenBio ASA Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA (OSL:BGBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0RU5:UK 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSL:BGBIO) Headlines

No Headlines

BerGenBio ASA (OSL:BGBIO) Cash-to-Debt : No Debt (1) (As of Mar. 2024)